KR101590834B1 - 중간엽 줄기 세포 분화 - Google Patents

중간엽 줄기 세포 분화 Download PDF

Info

Publication number
KR101590834B1
KR101590834B1 KR1020127001013A KR20127001013A KR101590834B1 KR 101590834 B1 KR101590834 B1 KR 101590834B1 KR 1020127001013 A KR1020127001013 A KR 1020127001013A KR 20127001013 A KR20127001013 A KR 20127001013A KR 101590834 B1 KR101590834 B1 KR 101590834B1
Authority
KR
South Korea
Prior art keywords
xaa
ser
leu
glu
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127001013A
Other languages
English (en)
Korean (ko)
Other versions
KR20120029472A (ko
Inventor
크리스틴 존슨
로리 제닝스
피터 슐츠
Original Assignee
더 스크립스 리서치 인스티튜트
아이알엠 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43450138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101590834(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 더 스크립스 리서치 인스티튜트, 아이알엠 엘엘씨 filed Critical 더 스크립스 리서치 인스티튜트
Publication of KR20120029472A publication Critical patent/KR20120029472A/ko
Application granted granted Critical
Publication of KR101590834B1 publication Critical patent/KR101590834B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020127001013A 2009-07-14 2010-07-13 중간엽 줄기 세포 분화 Expired - Fee Related KR101590834B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22529309P 2009-07-14 2009-07-14
US61/225,293 2009-07-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167002298A Division KR20160015403A (ko) 2009-07-14 2010-07-13 중간엽 줄기 세포 분화

Publications (2)

Publication Number Publication Date
KR20120029472A KR20120029472A (ko) 2012-03-26
KR101590834B1 true KR101590834B1 (ko) 2016-02-12

Family

ID=43450138

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020177036199A Ceased KR20180000337A (ko) 2009-07-14 2010-07-13 중간엽 줄기 세포 분화
KR1020167002298A Withdrawn KR20160015403A (ko) 2009-07-14 2010-07-13 중간엽 줄기 세포 분화
KR1020127001013A Expired - Fee Related KR101590834B1 (ko) 2009-07-14 2010-07-13 중간엽 줄기 세포 분화

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020177036199A Ceased KR20180000337A (ko) 2009-07-14 2010-07-13 중간엽 줄기 세포 분화
KR1020167002298A Withdrawn KR20160015403A (ko) 2009-07-14 2010-07-13 중간엽 줄기 세포 분화

Country Status (30)

Country Link
US (4) US9139633B2 (enExample)
EP (1) EP2453921B1 (enExample)
JP (1) JP5602850B2 (enExample)
KR (3) KR20180000337A (enExample)
CN (2) CN102625830B (enExample)
AU (1) AU2010273570B2 (enExample)
BR (1) BR112012000914B8 (enExample)
CA (1) CA2767826C (enExample)
CL (1) CL2012000091A1 (enExample)
CO (1) CO6491059A2 (enExample)
CR (1) CR20120024A (enExample)
CU (1) CU24042B1 (enExample)
EA (1) EA023073B1 (enExample)
EC (1) ECSP12011604A (enExample)
ES (1) ES2541217T3 (enExample)
GT (1) GT201200011A (enExample)
IL (2) IL217383A (enExample)
IN (1) IN2012DN00572A (enExample)
MA (1) MA33423B1 (enExample)
MX (1) MX2012000707A (enExample)
MY (1) MY160951A (enExample)
NZ (1) NZ597306A (enExample)
PE (2) PE20160507A1 (enExample)
PL (1) PL2453921T3 (enExample)
PT (1) PT2453921E (enExample)
SG (1) SG177318A1 (enExample)
TN (1) TN2011000655A1 (enExample)
UA (1) UA104031C2 (enExample)
WO (1) WO2011008773A2 (enExample)
ZA (1) ZA201200078B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160507A1 (es) * 2009-07-14 2016-05-20 Scripps Research Inst Diferenciacion de celulas madre mesenquimales
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
CN104185988B (zh) 2011-11-08 2019-05-10 韩国电子通信研究院 用于共享候选者列表的方法和装置
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
WO2014004465A1 (en) 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Targeted therapeutics
UY35368A (es) * 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
WO2014151953A1 (en) 2013-03-15 2014-09-25 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
UY36118A (es) 2014-05-13 2016-01-08 Novartis Ag Compuestos y composiciones para inducir condrogénesis
CN104840486A (zh) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 一种组合物及其应用、制剂
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
IL266361B2 (en) * 2016-11-14 2024-02-01 Novartis Ag Methods and preparations for the treatment of cartilage damage and arthritis
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
US12365692B2 (en) 2018-12-06 2025-07-22 Novartis Ag 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
WO2020115683A1 (en) 2018-12-06 2020-06-11 Novartis Ag 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068627A1 (en) * 2000-01-31 2003-04-10 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
WO1999058660A1 (en) 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
AU3661199A (en) 1998-04-27 1999-11-16 Zymogenetics Inc. Novel polypeptide growth factors and materials and methods for making them
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
AU768694B2 (en) 1999-03-08 2004-01-08 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AU4011300A (en) * 1999-07-20 2001-02-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
US20030120056A1 (en) * 2000-10-16 2003-06-26 Audrey Goddard TIE ligand homologues
AU2437702A (en) * 2000-10-16 2002-04-29 Genentech Inc Methods of treatment using wisp polypeptides
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
ES2429034T3 (es) * 2001-11-16 2013-11-12 Genentech, Inc. Uso de antagonistas de ANGPTL3 para el tratamiento de enfermedades hepáticas
GEP20074193B (en) * 2002-09-09 2007-09-10 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
CN101265503A (zh) * 2003-03-10 2008-09-17 独立行政法人科学技术振兴机构 检测间充质干细胞的标记和采用该标记识别间充质干细胞的方法
JP3979372B2 (ja) 2003-09-26 2007-09-19 ブラザー工業株式会社 画像処理装置、画像処理方法及び画像処理プログラム
EP1771196B1 (en) * 2004-06-21 2012-03-28 The Cleveland Clinic Foundation Ccr ligands for stem cell homing
US20110097330A1 (en) 2005-03-11 2011-04-28 Genentech, Inc. Novel Gene Disruptions, Compostitions and Methods Relating Thereto
WO2006127809A2 (en) 2005-05-24 2006-11-30 Whitehead Institute For Biomedical Research Methods for expansion and analysis of cultured hematopoietic stem cells
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
WO2008137641A2 (en) * 2007-05-04 2008-11-13 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
PE20160507A1 (es) * 2009-07-14 2016-05-20 Scripps Research Inst Diferenciacion de celulas madre mesenquimales
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068627A1 (en) * 2000-01-31 2003-04-10 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies

Also Published As

Publication number Publication date
MA33423B1 (fr) 2012-07-03
CN102625830A (zh) 2012-08-01
CN102625830B (zh) 2016-03-02
MY160951A (en) 2017-03-31
CA2767826A1 (en) 2011-01-20
BR112012000914A2 (pt) 2017-08-08
ES2541217T3 (es) 2015-07-16
BR112012000914B1 (pt) 2021-04-06
US20160213748A1 (en) 2016-07-28
EA201200118A1 (ru) 2012-09-28
ECSP12011604A (es) 2012-06-29
US11241482B2 (en) 2022-02-08
PE20120570A1 (es) 2012-05-19
IL217383A (en) 2016-08-31
EP2453921A2 (en) 2012-05-23
PT2453921E (pt) 2015-09-25
BR112012000914A8 (pt) 2017-12-19
UA104031C2 (uk) 2013-12-25
CR20120024A (es) 2012-06-11
GT201200011A (es) 2013-12-10
US10555990B2 (en) 2020-02-11
PL2453921T3 (pl) 2015-11-30
CN105601728A (zh) 2016-05-25
BR112012000914B8 (pt) 2021-05-25
JP2012533549A (ja) 2012-12-27
ZA201200078B (en) 2013-01-30
WO2011008773A3 (en) 2011-08-25
US10064918B2 (en) 2018-09-04
CU20120007A7 (es) 2013-02-26
US20120177644A1 (en) 2012-07-12
CL2012000091A1 (es) 2012-10-26
US20190000922A1 (en) 2019-01-03
CU24042B1 (es) 2014-11-27
CA2767826C (en) 2015-11-24
IN2012DN00572A (enExample) 2015-06-12
AU2010273570B2 (en) 2014-07-03
KR20160015403A (ko) 2016-02-12
JP5602850B2 (ja) 2014-10-08
SG177318A1 (en) 2012-03-29
IL247310B (en) 2018-04-30
EA023073B1 (ru) 2016-04-29
NZ597306A (en) 2014-03-28
US20200108122A1 (en) 2020-04-09
CO6491059A2 (es) 2012-07-31
CN105601728B (zh) 2020-01-10
HK1164169A1 (en) 2012-09-21
AU2010273570A1 (en) 2012-02-02
WO2011008773A2 (en) 2011-01-20
TN2011000655A1 (en) 2013-05-24
MX2012000707A (es) 2012-03-21
US9139633B2 (en) 2015-09-22
EP2453921B1 (en) 2015-05-27
EP2453921A4 (en) 2012-12-19
PE20160507A1 (es) 2016-05-20
IL217383A0 (en) 2012-02-29
KR20120029472A (ko) 2012-03-26
KR20180000337A (ko) 2018-01-02

Similar Documents

Publication Publication Date Title
KR101590834B1 (ko) 중간엽 줄기 세포 분화
JP6918871B2 (ja) 関節損傷の治療のためのペプチドおよび組成物
US20220402987A1 (en) Peptides and compositions for treatment of joint damage
HK1260928A1 (en) Peptides and compositions for treatment of joint damage
HK1164169B (en) Mesenchymal stem cell differentiation
HK1214754B (en) Peptides and compositions for treatment of joint damage

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A17-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20190103

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20200103

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240128

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240128